Related scientific articles (all)

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Authors : Saini KS, Azim HA, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2011
Journal : Breast
Volume : 20 Suppl 3
Pages : S20-7

Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?

Authors : Piccart-Gebhart M, Viale G, Ellis P, Abramowicz M, Carey L
Year : 2011
Journal : Ecancermedicalscience
Volume : 5(null)
Pages : 217

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

Authors : Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart-Gebhart M
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(6)
Pages : 547-58

Minimal residual disease and circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Reinholz M
Year : 2011
Journal : Breast Cancer Res
Volume : 13(5)
Pages : 222

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors : Bonnefoi H, Piccart-Gebhart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R
Year : 2011
Journal : Lancet Oncol
Volume : 12(6)
Pages : 527-39

Improving quality of life after breast cancer: dealing with symptoms.

Authors : Pinto AC, de Azambuja E
Year : 2011
Journal : Maturitas
Volume : 70(4)
Pages : 343-8

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Authors : Gianni L, Dafni U, Gelber Rd, de Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart M, Bell R
Year : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pages : 236-44

Treatment of febrile neutropenia is expensive: prevention is the answer.

Authors : Klastersky J, Paesmans M
Year : 2011
Journal : Onkologie
Volume : 34(5)
Pages : 226-8

New Imaging Techniques for 90Y Microsphere Radioembolization.

Authors : Vouche M, Vanderlinden B, Delatte P, Lemort M, Hendlisz A, Deleporte A, Garcia C, Flamen P
Year : 2011
Journal : J Nucl Med Radiat Ther
Volume : 2
Pages : 113

From best supportive care to early palliative care.

Authors : Klastersky J
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(4)
Pages : 311-2

Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.

Authors : Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS, Shi Q, Taphoorn MJ, Weis J, Bottomley A, + collaborators (among others :, Piccart-Gebhart M
Year : 2011
Journal : Expert Rev Pharmacoecon Outcomes Res
Volume : 11(5)
Pages : 587-99

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

Authors : Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X
Year : 2011
Journal : Eur. J. Cancer
Volume : 47(7)
Pages : 1037-45

Moterhood after Breast Cancer : searching for la dolce vita. Expert Rev.

Authors : Azim HA, Peccatori FA, de Azambuja E, Piccart-Gebhart M
Year : 2011
Journal : Anticancer Res
Volume : 11(2)
Pages : 287-298

Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.

Authors : Awada A, Saliba W, Bozovic-Spasojevic I
Year : 2011
Journal : Drugs Today (Barc)
Volume : 47(5)
Pages : 335-45

External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study.

Authors : Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW
Year : 2011
Journal : Cytometry B Clin Cytom
Volume : 80(2)
Pages : 112-8

Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.

Authors : Lalami Y, Awada A
Year : 2011
Journal : Curr Opin Oncol
Volume : 23(3)
Pages : 235-40

Prévention et traitement des infections. (TEXTBOOK : « Thérapeutique du cancer » Morère JF, Mornex F., Soulières D. 2ème édition. Springer-Verlag, Paris, France)

Authors : Klastersky J, Aoun M
Year : 2011
Journal : Book
Volume : -
Pages : 151-65

Supportive care for patients with gynaecological cancer

Authors : Klastersky J, Lossignol D
Year : 2011
Journal : South Afr Gynaecol Oncol
Volume : 3
Pages : 9-12

A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

Authors : Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A
Year : 2011
Journal : Clin Cancer Res
Volume : 17(21)
Pages : 6897-6904

A rare case of a pancreatic mass due to accessory spleen; when EUS-FNA is not enough.

Authors : Toussaint E, Flamen P, Demetter P, Matos C, Van Gossum M, Delhaye M, Closset J, Loi P, Deviere J, Arvanitakis M
Year : 2011
Journal : Endoscopy
Volume : 43 Suppl 2 UCTN(null)
Pages : E221-2